Interní Med. 2017; 19(3): 110-115 | DOI: 10.36290/int.2017.021

Innovations in treatment of IBD

MUDr. Tomáš Douda, Ph.D.
II. interní gastroenterologická klinika, Subkatedra gastroenterologie, Lékařská fakulta UK, Centrum pro idiopatické střevní záněty, Fakultní nemocnice Hradec Králové

The steady advances in the treatment of IBD for the past decade have been quite significant. The changes concern all of the steps

in the treatment pyramid. The changes involve the surgical approach to treatment, method of aminosalicylate administration

in ulcerative colitis, the use of new slow release tablets by means of MMX, optimization of azathioprine treatment a resumption

methotrexate treatment comes into play. New biologics have been established in the past decade, particularly biosimilar anti-TNF.

New possibilities of IBD treatment with different mechanism of action apart from the anti-TNF are discovered nowadays.

Keywords: IBD, Ulcerative colitis, Crohn disease, therapy, mesalazine, corticosteroids, MMX, azathioprine, methotrexate, anti-TNFα, vedolizumab, etrolizumab, ustekinumab, tofacitinib

Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Douda T. Innovations in treatment of IBD. Interní Med. 2017;19(3):110-115. doi: 10.36290/int.2017.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neurath M. Cytokines in inflammatory bowel disease. Nature Reviews. 2014; 14: 329-342. Go to original source... Go to PubMed...
    2. Dave M, et al. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin N Am. 2014; 43: 405-424. Go to original source... Go to PubMed...
    3. Burisch J, et al. The burden of inflammatory bowel disease in Europe, Journal of Crohn's and Colitis 2013. Go to original source... Go to PubMed...
    4. Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015.
    5. Serclová Z. Fast track in intestinal surgery; current review; Rozhl Chir. 2009; 88(9): 527-535. Go to PubMed...
    6. Prokopová L, Ďuricová D, Bortlík M, Zbořil V, Lukáš M. Doporučené postupy pro podávání aminosalicylátů u nemocných s idiopatickými střevními záněty. Gastroent Hepatol 2012; 66(5): 391-400.
    7. Ďuricová D. Mesalazin u Crohnovy nemoci: obsolentní nebo neprávem opomíjená léčba? Gastroent Hepatol 2013; 67(1): 22-24.
    8. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016; (5): CD000544. Go to original source...
    9. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58(2): 233-240. doi: 10.1136/gut.2008.154302. Go to original source... Go to PubMed...
    10. Ferring Pharmaceuticals. CORTIMENT 9 mg SPC. [online]. Available from: www.medicines.org.uk/emc/medicine/30253.
    11. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143(5): 1218-1226. e1-2. doi: 10.1053/j.gastro.2012.08.003. Go to original source... Go to PubMed...
    12. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63(3): 433-441. doi: 10.1136/gutjnl-2012-304258. Go to original source... Go to PubMed...
    13. Hrdlička L, Bortlík M, Douda T, Drastich P, Falt P, Matějková P, Koželuhová J, Liberda M, Nedbalová L, Novotný A, Kolář M, Lukáš M. Budesonid MMX (Cortiment(R) 9 mg) v léčbě ulcerózní kolitidy v reálné klinické praxi; Gastroent Hepatol 2016; 70(6): 509-513. Go to original source...
    14. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9: CD000478. Go to original source... Go to PubMed...
    15. Moreau AC, Paul S, Del Tedesco E, et al. Association Between 6-Thioguanine Nucleotides Levels and Clinical Remission in Inflammatory Disease: a Meta-analysis. Inflamm Bowel Dis 2014; 20: 464-471. Go to original source... Go to PubMed...
    16. Smith M, Blaker P, Patel C, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 2013; 67: 161-169. Go to original source... Go to PubMed...
    17. Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohn Colitis 2012; 6: 905-912. Go to original source... Go to PubMed...
    18. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 363-369. Go to original source... Go to PubMed...
    19. Edouard Louis; Peter Irving; Laurent Beaugerie: Use of Azathioprine in IBD: Modern Aspects of an Old Drug; Gut. 2014; 63(11): 1695-1699. Go to original source... Go to PubMed...
    20. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut 2012; 61: 476-483. Go to original source... Go to PubMed...
    21. Decaux et al. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med. 2000; 135(3): 256-262. Go to original source... Go to PubMed...
    22. Thomas, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003; 9(4): 237-245. Go to original source... Go to PubMed...
    23. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group.: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15): 1383-1395. Go to original source... Go to PubMed...
    24. Yarur AJ, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015; 13(6): 1118-24.e3. Go to original source... Go to PubMed...
    25. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-297. Go to original source... Go to PubMed...
    26. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-? biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013; 145: 1464-1478. Go to original source... Go to PubMed...
    27. McDonald JWD, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews 2014. Go to original source...
    28. Patel V, Wang Y, MacDonald JK, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2014; 8: CD006884. Go to original source... Go to PubMed...
    29. Feagan BG, McDonald JWD, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology. 2014; 146: 681-688. Go to original source... Go to PubMed...
    30. Hans H. Herfarth, MD, PhD, Michael D. Kappelman, MD, MPH, Millie D. Long, MD, MPH, and Kim L. Isaacs, MD, PhD Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases Inflamm Bowel Dis 2016; 22: 224-233. Go to original source... Go to PubMed...
    31. Swaminath A, Taunk R, Lawlor G. Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide. World J Gastrointest Pharmacol Ther 2014; 5(3): 113-121. Go to original source... Go to PubMed...
    32. Bortlík M, et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: třetí, aktualizované vydání Gastroent Hepatol 2016; 70(1): 11-26. doi:10.14735/amgh201611. Go to original source...
    33. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-653. Go to original source... Go to PubMed...
    34. Danese S, Fiorino G, Peyrin-Biroulet L. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160: 704-711. Go to original source... Go to PubMed...
    35. Park W, Yoo DH, Jaworski J, et al. PLANETAS study. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016; 18: 25. doi: 10.1186/s13075-016-0930-4. Go to original source... Go to PubMed...
    36. Yoo DH, Racewicz A, Brzezicki J et al PLANETRA study. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016; 18: 82. doi: 10.1186/s13075-016-0981-6. Go to original source... Go to PubMed...
    37. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study J Gastroenterol Hepatol. 2015; 30(12): 1705-1712. doi: 10.1111/jgh.12997. Go to original source... Go to PubMed...
    38. Jahnsen J, Detlie TE, Vatn S, et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015; 9(Suppl 1): 45-52. doi: 10.1586/17474124.2015.1091308 Go to original source... Go to PubMed...
    39. Maser AE, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006. Go to original source... Go to PubMed...
    40. von Andrian UH & B Engelhardt. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72. Go to original source... Go to PubMed...
    41. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol. 2011; 12(6): 485-491. Go to original source... Go to PubMed...
    42. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330(3): 864-875. Go to original source... Go to PubMed...
    43. Sandborn, WJ. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925. Go to original source... Go to PubMed...
    44. Danese S, Panes. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. J. Gastroenterology 2014; 147: 981-989. Go to original source... Go to PubMed...
    45. Briskin M, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissu. Am J Pathol 1997; 151(1): 97-110.
    46. Van Assche, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. NEJM 2005; 353(4): 362-368. Go to original source... Go to PubMed...
    47. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47. Go to original source... Go to PubMed...
    48. Tan C, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437. Go to original source... Go to PubMed...
    49. von Andrian UH, et al. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343(14): 1020-1034. Go to original source... Go to PubMed...
    50. Bryant RV, et al. Introducing Vedolizumab to Clinical Practice: Who, When, and How? Journal of Crohn's and Colitis, 2015: 356-366. Go to original source... Go to PubMed...
    51. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014; 384: 309-318. Go to original source... Go to PubMed...
    52. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-?-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63(4): 567-577. Go to original source... Go to PubMed...
    53. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-1528. Go to original source... Go to PubMed...
    54. Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-The McGill experience. J Crohns Colitis 2014 pii: S1873-9946 (e-pub ahead of print). Go to original source... Go to PubMed...
    55. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.